Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）

• Status: Unknown status
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators evaluate the effectiveness and safeness of low-dose Recombinant Human Interleukin-2 （rhIL-2） for MAS.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking University People's Hospital
• Treatments: Aldesleukin; Interleukin-2

Criteria

Inclusion Criteria:

• Diagnosis of Macrophage Activation Syndrome（MAS）

• MAS secondary to autoimmune disease, such as Adult onset still's disease (AOSD), juvenile rheumatoid arthritis (JRA) or Systemic Lupus Erythematosus (SLE).

Exclusion Criteria:

• Primary MAS

• Secondary to neoplasia, lymphoma and virus infection

• pre-treatment with Cyclosporine A

• relevant cardiac, pulmonary, neurologic or psychiatric disease

• life-Vaccination within 4 weeks before begin with study medication

• pregnant or breast-feeding

• weight under 45kg or more than 80kg